Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives

Biochemical Pharmacology

Volumn 69, Issue 10, 2005, Pages 1501-1508

  Eyal, Sara ^a   Yagen, Boris ^a   Shimshoni, Jakob ^a   Bialer, Meir ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Anticancer drugs; Antiepileptic drugs; Histone deacetylase; Valproic acid; Valproic acid constitutional isomers

Indexed keywords

DRUG METABOLITE; HISTONE DEACETYLASE; LYSINE; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ACETYLATION; ARTICLE; CELL CYCLE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SUBSTRATE; HELA CELL; HUMAN; HUMAN CELL; IC 50; IN VIVO CULTURE; ISOMER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR CELL;

EID: 18044381744     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.02.012     Document Type: Article

References (45)

1. B.F.D. Bourgeois Valproic acid - clinical efficacy and use in epilepsy R.H. Levy R.H. Mattson B.S. Meldrum E. Perucca Antiepileptic drugs 2002 Lippincot Williams & Wilkins Philadelphia 808 817
2. S.D. Silberstein Clinical efficacy and use in other neurological disorders R.H. Levy R.H. Mattson B.S. Meldrum E. Perucca Antiepileptic drugs 2002 Lippincot Williams & Wilkins Philadelphia 818 827
3. C.M. Regan Therapeutic levels of sodium valproate inhibit mitotic indices in cells of neural origin Brain Res 347 1985 394 398
4. M.L. Martin, and C.M. Regan The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase Brain Res 554 1991 223 228
5. R. Tang, A.M. Faussat, P. Majdak, J.Y. Perrot, D. Chaoui, and O. Legrand Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1 Leukemia 18 2004 1246 1251
6. A. Lampen, S. Siehler, U. Ellerbeck, M. Gottlicher, and H. Nau New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta) Toxicol Appl Pharmacol 160 1999 238 249
7. U. Werling, S. Siehler, M. Litfin, H. Nau, and M. Gottlicher Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivatives Mol Pharmacol 59 2001 1269 1276
8. M. Göttlicher, S. Minucci, P. Zhu, O.H. Kramer, A. Schimpf, and S. Giavara Valproic acid defines a novel class of HDACs inhibitors inducing differentiation of transformed cells EMBO J 20 2001 6969 6978
9. J. Cinatl Jr., J. Cinatl, P.H. Driever, R. Kotchetkov, P. Pouckova, and B. Kornhuber Sodium valproate inhibits in vivo growth of human neuroblastoma cells Anticancer Drugs 8 1997 958 963
10. J. Cinatl Jr., J. Cinatl, M. Scholz, P.H. Driever, D. Henrich, and H. Kabickova Antitumor activity of sodium valproate in cultures of human neuroblastoma cells Anticancer Drugs 7 1996 766 773
11. R.A. Blaheta, and J. Cinatl Anti-tumor mechanisms of valproate: a novel role for an old drug Med Res Rev 22 2002 492 511
12. R.A. Blaheta, H. Nau, M. Michaelis, and J. Cinatl Jr. Valproate and valproate-analogues: potent tools to fight against cancer Curr Med Chem 9 2002 1417 1433
13. F. McLaughlin, and N.B. La Thangue Histone deacetylase inhibitors open new doors in cancer therapy Biochem Pharmacol 68 2004 1139 1144
14. G. Chen, L.D. Huang, Y.M. Jiang, and H.K. Manji The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3 J Neurochem 72 1999 1327 1330
15. C.J. Phiel, F. Zhang, E.Y. Huang, M.G. Guenther, M.A. Lazar, and P.S. Klein Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J Biol Chem 276 2001 36734 36741
16. D. Eikel, A. Lampen, and H. Nau Histonedeacetylases are new molecular targets whose inhibition can cause birth defects: evidence from structure-activity relationship of valproic acid derivatives Reprod Toxicol 18 2004 723 724
17. P.A. Marks, R.A. Rifkind, V.M. Richon, R. Breslow, T. Miller, and W.K. Kelly Histone deacetylases and cancer: causes and therapies Nature Rev Cancer 1 2001 194 202
18. R.W. Johnstone Histone-deacetylase inhibitors: novel drugs for the treatment of cancer Nature Rev Drug Discov 1 2002 287 299
19. V. Santini, A. Gozzini, B. Scappini, A. Grossi, and P. Rossi Ferrini Searching for the magic bullet against cancer: the butyrate saga Leuk Lymphoma 42 2001 275 289
20. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8:718-28.
21. N. Gurvich, O.M. Tsygankova, J.L. Meinkoth, and P.S. Klein Histone deacetylase is a target of valproic acid-mediated cellular differentiation Cancer Res 64 2004 1079 1086
22. N. Isoherranen, B. Yagen, and M. Bialer New CNS-active drugs which are second-generation valproic acid. Can they lead to the development of a magic bullet? Curr Opin Neurol 16 2003 203 211
23. M. Radatz, K. Ehler, B. Yagen, M. Bialer, and H. Nau Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid Epilespy Res 1998 30 1998 41 48
24. U. Bojic, M.M. Elmazar, R.S. Hauck, and H. Nau Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect Chem Res Toxicol 9 1996 866 870
25. I. Isoherranen, H.S. White, R.H. Finnell, B. Yagen, J.H. Woodhead, and K.S. Bennett Anticonvulsant profile and teratogenicity of N-methylcyclopropyl carboxamide: A new antiepileptic drug Epilespia 43 2002 115 126
26. E. Sobol, M. Bialer, and B. Yagen Tetramethylcyclopropyl analogues of a leading antiepileptic drug - valproic acid. Synthesis and evaluation of the anticonvulsant activity of its amide deraivatives J. Med Chem 47 2004 4316 4326
27. A. Haj-Yehia, and M. Bialer Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity J Pharm Sci 79 1990 719 724
28. M. Radatz, K. Ehlers, B. Yagen, M. Bialer, and H. Nau Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid Epilepsy Res 30 1998 41 48
29. K. Ito, S. Lim, G. Caramori, B. Cosio, K.F. Chung, and I.M. Adcock A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression Proc Natl Acad Sci U.S.A. 99 2002 8921 8926
30. O.H. Lowry, N.J. Rosenbrough, A.L. Farr, and R.J. Randell Protein measurement with folin phenol reagent J Biol Chem 193 1951 265 275
31. S.I. Johannessen, D. Battino, D.J. Berry, M. Bialer, G. Kramer, and T. Tomson Therapeutic drug monitoring of the newer antiepileptic drugs Ther Drug Monit 25 2003 347 363
32. J.J. Buggy, M.L. Sideris, P. Mak, D.D. Lorimer, B. McIntosh, and J.M. Clark Cloning and characterization of a novel human histone deacetylase. HDAC8 Biochem J 350 2000 199 205
33. C.A. Hassig, J.K. Tong, T.C. Fleischer, T. Owa, P.G. Grable, and D.E. Ayer A role for histone deacetylase activity in HDAC1-mediated transcriptional repression Proc Natl Acad Sci U.S.A. 95 1998 3519 3524
34. E.Y. Huang, J. Zhang, E.A. Miska, M.G. Guenther, T. Kouzarides, and M.A. Lazar Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway Genes Dev 14 2000 45 54
35. J.J. Tong, J. Liu, N.R. Bertos, and X.J. Yang Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain Nucleic Acids Res 30 2002 1114 1123
36. T.A. Miller, D.J. Witter, and S. Belvedere Histone deacetylase inhibitors J Med Chem 46 2003 5097 5116
37. M.S. Finnin, J.R. Donigian, A. Cohen, V.M. Richon, R.A. Rifkind, and P.A. Marks Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 401 1999 188 193
38. L. Michalik, B. Desvergne, and W. Wahli Peroxisome-proliferator-activated receptors and cancers: complex stories Nature Rev Cancer 4 2004 61 70
39. M. Bordonaro, J.M. Mariadason, F. Aslam, B.G. Heerdt, and L.H. Augenlicht Butyrate-induced apoptotic cascade in colonic carcinoma cells: modulation of the beta-catenin-Tcf pathway and concordance with effects of sulindac and trichostatin A but not curcumin Cell Growth Differ 10 1999 713 720
40. N. Takai, J.C. Desmond, T. Kumagai, D. Gui, J.W. Said, and S. Whittaker Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells Clin Cancer Res 10 2004 1141 1149
41. H. Nau, and W. Loscher Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice Fundam Appl Toxicol 6 1986 669 676
42. H. Nau Valproic acid teratogenicity in mice after various administration and phenobarbital-pretreatment regimens: the parent drug and not one of the metabolites assayed is implicated as teratogen Fundam Appl Toxicol. 6 1986 662 668
43. R.S. Hauck, and H. Nau The enantiomers of the valproic acid analogue 2-N-propyl-4-pentynoic acid (4-yn-VPA): asymmetric synthesis and highly stereoselective teratogenicity in mice Pharm Res 9 1992 850 855
44. R.H. Finnell, G.D. Bennett, S.B. Karras, and V.K. Mohl Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite Teratology 38 1988 313 320
45. H. Nau, R.S. Hauck, and K. Ehlers Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms Pharmacol Toxicol 69 1991 310 321